Inclusion Criteria:

• Diagnosis of idiopathic Parkinson’s disease (according to modified Hoehn & Yahr
criteria Stages I-III.)
•Subjects aged 30 years or greater at screening. Women of child-bearing potential
must be practicing a clinically accepted method of contraception during the study and
for at least one month prior to randomization and one month following completion of
the study. Acceptable contraceptive methods include abstinence, oral contraception,
injectable progestogen, implants of levonorgestrel, estrogenic vaginal ring,
percutaneous contraceptive patches, surgical sterilisation, male partner sterilization,
intrauterine device [IUD], or double barrier method: condom or occlusive cap
(diaphragm or cervical/vault caps) plus spermicidal agent
(foam/gel/film/cream/suppository.
•A baseline UPDRS motor score of at least 10.
•Limited prior exposure to low or moderate doses of L-DOPA (up to 3 months in total)
or dopamine agonists including ropinirole (up to 6 months in total) is allowed
provided treatment is discontinued for a minimum of 4 weeks prior to screening.
•Provide written informed consent for this study.
•Be willing and able to comply with study procedures.

Exclusion Criteria:

•Subjects with Parkinson’s disease in whom dopaminergic therapy is not warranted at
the time of screening.
•Subjects with severe, clinically significant condition(s) other than Parkinson’s disease
which, in the opinion of the investigator, render the subject unsuitable for the
study (e.g., psychiatric, haematological, renal, hepatic, endocrinology, neurological
[other than Parkinson’s disease], cardiovascular, or active malignancy [other than
basal cell carcinoma]).
•Subjects with crippling degenerative arthritis or other physical or mental conditions
precluding accurate assessment of efficacy or safety.
•Subjects with prior or current major psychosis (e.g., schizophrenia or psychotic
depression) e.g. scoring 3 or 4 on UPDRS item 2 [thought disorder] or item 3
[depression].
•Subjects with severe clinical dementia e.g. scoring 3 or 4 on UPDRS item 1
[mentation].
•Subjects with severe dizziness or fainting due to postural hypotension on standing.
•Subjects with a personal history of melanoma.
•Subjects with clinically significant abnormalities in laboratory or ECG tests at
Screening. If findings are outside the normal range and the subject is included, it
must be documented by the investigator that the findings are not of clinical
significance.
•Subjects diagnosed with an impulse control disorder. The modified MIDI
will be conducted at screening. Subjects who score positive for this screen must be
referred to a specialist for diagnostic evaluation prior to enrolling (screening) in the
study.
•Subjects with an active suicidal plan/intent or have had active suicidal thoughts
in the past 6 months. Subjects with a history of suicide attempt in the last 2
years or more than 1 lifetime suicide attempt.
•Current alcohol or drug dependence.
•Definite or suspected personal or family history of clinically significant adverse
reactions or hypersensitivity to ropinirole (or to drugs with a similar chemical
structure) that would preclude long-term dosing with ropinirole.
•Withdrawal, introduction, or change in dose of hormone replacement therapy and/or
any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacine, fluvoxamine,
cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7
days prior to baseline (randomization).
•Subjects on chronic therapy with any of these agents may be enrolled but
doses must have remained stable from 7 days prior to baseline (randomization)
through the end of the treatment period. Smokers should maintain normal
smoking habit.
•Women who are pregnant or breast-feeding.
•Use of an investigational drug from 30 days or 5 half-lives (which ever is longer)
prior to baseline (randomization) to the end of the treatment period.

• United States (click to view all sites in United States)
• Florida (click to view)
• GSK Investigational Site
  Tampa, Florida, 33612; RECRUITING;
  Contact: Theresa A. Zesiewicz, Principal Investigator, .